載入...
How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma
In 2011, two therapies were approved for the treatment of metastatic melanoma: ipilimumab, an immunotherapeutic agent, and vemurafenib, a BRAF kinase inhibitor. These approvals were based on data from phase III trials, which showed that treatment with these agents produced substantial improvements i...
Na minha lista:
| 發表在: | Ann Oncol |
|---|---|
| 主要作者: | |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Oxford University Press
2012
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6278954/ https://ncbi.nlm.nih.gov/pubmed/22918923 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mds258 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|